Clinical Trials Logo

Dementia, Vascular clinical trials

View clinical trials related to Dementia, Vascular.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03785067 Terminated - Hypertension Clinical Trials

Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT) Cognitive Sub-Study

TRIDENT COG
Start date: February 27, 2020
Phase: Phase 3
Study type: Interventional

A Sub-Study of an investigator initiated and conducted, multicentre, international, double-blinded, placebo-controlled, parallel-group, randomised controlled trial (TRIDENT) to determine the effect of more intensive long-term blood pressure control, provided by a fixed low-dose combination blood pressure lowering pill ("Triple Pill") strategy on top of standard of care, for slowing memory decline as measured by Cambridge Neuropsychological Test Automated Battery (CANTAB), in patients with a history of acute stroke due to intracerebral haemorrhage (ICH).

NCT ID: NCT03783754 Terminated - Stroke Clinical Trials

Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial Magnetic Resonance Imaging Sub-study

TRIDENT-MRI
Start date: August 9, 2018
Phase: N/A
Study type: Interventional

TRIDENT Main Study: TRIDENT is a multicentre, international, double-blinded, placebo-controlled, parallel-group, randomised controlled trial of a fixed low-dose combination BP-lowering pill ("Triple Pill") strategy on top of standard of care, in patients with a history of acute intracerebral haemorrhage (ICH) and systolic blood pressure (SBP) levels defined as 'high normal to borderline high', and on either minimal or no BP-lowering treatment according to current guidelines. MRI Sub-Study Centres capable of specific MRI of the brain sequences will be identified. The patients in the TRIDENT main study who are identified to be eligible for the MRI Sub-Study will undergo MRI scans at baseline (6 weeks to 6 months post-randomisation) and at 36-month follow-up time points. All data collected will be analysed centrally at the Brain and Mind Centre (BMC) in Sydney, Australia.

NCT ID: NCT01815112 Terminated - Alzheimer Disease Clinical Trials

Early Diagnosis of Alzheimer-like Dementia: Benefit of MRI and PET Imaging

Start date: February 2008
Phase: N/A
Study type: Interventional

The physio-pathology of Alzheimer's disease (AD) remains unknown and there is no cure. Thus, the search for objective markers of preclinical first signs of cognitive impairment, is currently a major public health issue. Early detection of the disease is a major challenge to hope to slow or even stop the neurodegenerative process before the stage of dementia. In AD the investigators observe: - A reduction in the volume of brain hippocampi associated with an alteration of the diffusion of water molecules in the white matter. - A structural brain degeneration coupled with a decrease in cerebral glucose metabolism. Recent publications show that cerebrospinal fluid (CSF)flow is also altered, probably due to dysfunction of the choroid plexus. Hence the potential interest to study is, in addition to conventional imaging, the imaging of CSF dynamics and choroid plexus metabolism. In that aim,the investigators use two imaging modalities: - Magnetic resonance imaging (MRI) is used to assess blood and CSF flow in the brain - Positron emission tomography (PET) is used to assess glucose metabolism in grey/white matter and also in choroid plexus. The investigators expect that, because of choroid plexus atrophy in AD, CSF flow would be altered as well as glucose metabolism dynamic in choroid plexus.

NCT ID: NCT00174382 Terminated - Dementia, Vascular Clinical Trials

Vaspect Study - An Open-Label Trial Of Donepezil in Vascular and Mixed Dementia

Start date: June 2005
Phase: Phase 3
Study type: Interventional

To document effectiveness, safety, and tolerability of donepezil in patients with mixed AD/VaD, and to further document the effectiveness, safety, and tolerability of donepezil in patients with VaD. The effects of donepezil on executive functioning, behavior, general cognition, ADLs and global functioning will be assessed.